Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Drugs In Development, 2024 report and make more profitable business decisions.
Neurofibromatosis type 1 (NF1), also called von Recklinghausen’s disease, is a rare genetic disorder characterized by the development of multiple noncancerous (benign) tumors of nerves and skin (neurofibromas). This is transmitted on chromosome 17 and is caused by mutation of the NF1 gene. Symptoms include liver enlargement, glioma, Lisch nodules, and pheochromocytoma. Treatment includes pain medications, surgery, chemotherapy, and radiation therapy.
The Neurofibromatoses Type I (Von Recklinghausen’s Disease) drugs in development market research report provide comprehensive information on the therapeutics under development for Neurofibromatoses Type I (Von Recklinghausen’s Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neurofibromatoses Type I (Von Recklinghausen’s Disease) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Neurofibromatoses Type I (Von Recklinghausen's Disease) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 26 molecules, with 24 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Neurofibromatoses Type I (Von Recklinghausen’s Disease) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Neurofibromatoses Type I (Von Recklinghausen’s Disease) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Neurofibromatoses Type I (Von Recklinghausen’s Disease) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Advenchen Laboratories LLCAlexion Pharmaceuticals Inc
AstraZeneca Plc
Astrogen Ltd
Binjiang Pharma
Inc.
BioMed Valley Discoveries Inc
Bristol-Myers Squibb Co
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Cincinnati Children's Hospital Medical Center
Eli Lilly and Co
Fochon Pharmaceutical Ltd
Healx Ltd
Infixion Bioscience Inc
Mulberry Biotherapeutics Inc
NFlection Therapeutics Inc
Novartis AG
Pasithea Therapeutics Corp
Pfizer Inc
Shanghai Sunway Biotech Co Ltd
SpringWorks Therapeutics Inc
Therillume Inc
University of Alabama
Vyriad Inc
Table of Contents
Table
Figures
Frequently asked questions